

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

138

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 9/00, 9/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/33809</b> <b>(43) International Publication Date:</b> 15 June 2000 (15.06.00)
<b>(21) International Application Number:</b> PCT/EP99/09536 <b>(22) International Filing Date:</b> 6 December 1999 (06.12.99) <b>(30) Priority Data:</b> MI98A002655 10 December 1998 (10.12.98) IT <b>(71) Applicant (for all designated States except US):</b> MEDIO- OLANUM FARMACEUTICI S.P.A. [IT/IT]; Via S. Giuseppe Cottolengo, 15, I-20143 Milan (IT). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MAQUIN, Alain [FR/FR]; 29, allée du Montchaillou, Pomponne, F-77400 Lagny sur Marne (FR). MAURIAC, Patrice [FR/FR]; 54, rue de Picpus, F-75012 Paris (FR). MARION, Pierre [FR/FR]; 26, avenue du Centre Prolongée, F-93360 Neuilly Plaisance (FR). <b>(74) Agent:</b> PASSINI, Angelo; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> COMPOSITIONS CONTAINING A PEPTIDE AND POLYLACTIC-GLYCOLIC ACID SUITABLE FOR PREPARING SUBCUTANEOUS IMPLANTS WITH AN EXTENDED RELEASE PERIOD		
<b>(57) Abstract</b>  Compositions comprising a peptide and polylactic-glycolic acid (PLGA) wherein the distribution of the size of the particles of the peptide in the PLGA results highly heterogeneous, suitable to the preparation of subcutaneous implants having a release time at least equal to 6 months.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOSITIONS CONTAINING A PEPTIDE AND POLYLACTIC-GLYCOLIC  
ACID SUITABLE FOR PREPARING SUBCUTANEOUS IMPLANTS WITH AN  
EXTENDED RELEASE PERIOD

**Field of the invention**

5 The present invention refers to compositions comprising a peptide and polylactic-glycolic acid suitable for the preparation of subcutaneous implants.

**Prior art**

Compositions made up of mixtures of a drug with a polymer of lactic acid or a polymer of glycolic acid or with a copolymer of lactic acid and glycolic acid, as  
10 described in the U.S. patent 3.773.919 (Du Pont) are well known.

These compositions are indicated for parenteral administration and have the characteristics of releasing effective quantities of the drug over a set period of time.

The drug and the polymeric substance can be combined in accordance with any of  
15 the known techniques or the particles of the drug can be coated in the polymer operating in accordance with known techniques.

The U.S. patent 4.767.628 (ICI) describes compositions containing a peptide and a polymer of lactic acid or a copolymer of lactic acid and glycolic acid.

When preparing the compositions, the peptide and the (co)polymer are dissolved  
20 in a solvent which can be the same or different for the two substances, for Example dioxane or water, and then the two solutions are mixed.

The subsequent operations consist of removing the solvent at low temperature and in extruding the powder obtained in this way.

In this way a composition in the form of cylinders is obtained in which the peptide  
25 is distributed homogeneously throughout the polymer.

It is already known from the U.S. patent 5.366.734 (Zeneca) that the compositions covered by the U.S. patent 4.767.628 referred to above can be used in preparing subcutaneous implants.

The polymer of lactic acid and the copolymer of lactic acid and glycolic acid are  
30 incompatible with the peptide therefore diffusion of the peptide through the polymer is impossible.

When these implants are introduced into a buffer solution at 37 °C, the water

penetrates and diffuses in the implant and is distributed between the polymer and the peptide forming regions of hydrated peptides.

The first stage in releasing the peptide described in the U.S. patent 5.366.734 is a stage of diffusion caused by the polymer swelling.

5 When the polymer swells this allows channels of hydrated peptide to form where the peptide diffuses to the surface.

If swelling stops, the peptide is no longer released.

The second stage of release is caused by the polymer matrix degrading.

10 During this stage holes and cracks form in the matrix which allow the release of the hydrated peptides which are still isolated in the matrix.

The total release time is limited to the sum of the release times for each stage.

However the maximum release time observed is in the order of three months.

15 In the application for international patent WO 98/09613 (Deghenghi) a process for preparing subcutaneous implants capable of releasing bioactive peptides is described.

This process consists of the following stages:

- milling a copolymer of lactic acid and glycolic acid,
- wetting the copolymer with an aqueous slurry of a peptide (in the Examples an aqueous solution of avoreline acetate is used):
- 20 • mixing this copolymer with the aforementioned slurry so as to obtain a homogeneous mixture;
- drying this mixture at a temperature of no higher than 25°C;
- extruding the mixture at 70-110°C in order to obtain small extruded cylinders suitable for use as subcutaneous implants.

25 This process cannot be carried out using industrial methods because it is not possible to sufficiently eliminate water from the mixture. The results declared in WO 98/109613 cannot therefore be reproduced.

30 However the fundamental characteristic of the compositions for subcutaneous implants in the patents referred to above consists of the homogeneous distribution of the peptide in the polymeric substance, resulting from using a solution of at least one of the two components.

The implants currently on the market have the disadvantage of releasing the

peptides over a limited period of time, generally of around 3 months.

### **Summary of the invention**

The applicant has now found compositions suitable for preparing subcutaneous implants which allow the active substance to be released over a period of time of  
5 at least 6 months.

These compositions consist of a polylactic-glycolic acid (PLGA) and a peptide and have the characteristic of distributing peptide particles in the PLGA whose dimensions, under microscopic examination, are extremely heterogeneous, with peptide particles of diameter of between 1 and 60 micrometres dispersed in the  
10 polymer matrix.

These and other characteristics of the compositions in accordance with the invention and the process for preparing them will be illustrated in greater depth in the following detailed description.

### **Brief description of the drawings**

15 Figure 1 represents a microscope test of a cross section of an implant according to the invention.

Figure 2 represents a microscope test of a cross section of an implant according to the prior art.

Figure 3 represents the cumulative amount of avoreline released from implants of  
20 Example 1.

Figure 4 represents the cumulative amount of avoreline released from implants of Example 2.

Figure 5 represents the plasmatic concentration of LH, FSH and testosterone by clinical experimentation using implants having an avoreline content of 10 mg.

25 Figure 6 represents the plasmatic concentration of LH, FSH and testosterone by clinical experimentation using implants having an avoreline content of 15 mg.

Figure 7 represents the plasmatic concentration of avoreline and testosterone by clinical experimentation using implants having an avoreline content of 10 mg.

Figure 8 represents the plasmatic concentration of avoreline and testosterone by  
30 clinical experimentation using implants having an avoreline content of 15 mg.

### **Detailed description of the invention**

This invention refers to compositions consisting of polylactic-glycolic acid (PLGA)

and a peptide suitable for the preparation of long-release subcutaneous implants. The implants prepared from compositions in accordance with this invention consist of a PLGA matrix of a high molecular weight incorporating a peptide in the form of particles having extremely heterogeneous dimensions.

- 5 This structure allows the peptide to be released in three stages, which are, respectively: pure diffusion, diffusion with swelling of the PLGA and release caused by PLGA degradation.

This allows the total release time to be significantly increased.

- 10 When these implants are introduced into an aqueous environment the water diffuses through the polymer matrix, reaches the peptide particles closest to the surface and then the more internal zones, resulting in the formation of a porous lattice of the hydrated peptide, through which the phenomenon of peptide release via pure diffusion (first stage) occurs.

- 15 The implant remains unchanged for approximately 6 weeks and over this period releases approximately 30% of the peptide.

The duration of this pure diffusion stage is essentially determined by the degree of heterogeneity of the dimensions of the peptide particles and the speed is essentially determined by the peptide content in the PLGA matrix.

- 20 As a result of the wide diversity in the dimensions of the peptide granules, a sufficient quantity of peptide remains after the first stage of dissolution to be released over the subsequent stages.

In the second stage the peptide is released by diffusion with swelling of the polymer.

In the third stage, the residual peptide is released when the matrix is destroyed.

- 25 The succession of the three stages for releasing the peptide without dead time depends on the appropriate choice of constituents in the composition, in particular:

- the heterogeneous nature of the dimensions of the peptide particles determines the first stage of release;
  - the characteristics of the PLGA (molecular weight and molar ratio) have an
- 30 influence on the stages of the swelling and matrix degradation.

The technical difficulty of this invention lies in retaining the heterogeneous nature of the dimensions of the peptide particles throughout the process for preparing the

implants.

This difficulty cannot be overcome by using the known techniques of mixing by dissolving in a solvent shared by the two compounds or in one solvent for one of the two compounds, nor by means of the techniques for mixing in the melted state.

- 5 This difficulty has been resolved in this invention by means of wet granulation of the PLGA with the peptide. This operation and the subsequent operations allow the initial heterogeneity of the peptide particles to be retained.

The invention also refers to the process for preparing these compositions and to the aforementioned subcutaneous implants.

- 10 One such process is a wet granulation process.

This process consists of the following stages:

- a) the peptide in the form of particles having a diameter of between 1 and 60 micrometres is homogeneously mixed when dry with PLGA in the form of particles whose granulometry is between 10 to 150, preferably 50 and 150, micrometres;
- 15 b) the mixture obtained from stage a) is granulated using wet granulation by adding a suitable liquid, for example ethanol or water;
- c) the granulate is then dried until the residual liquid content is 0.1-3.0%, preferably 0.5-2.0% by weight. This liquid content is fundamental in that it gives the granule sufficient cohesion to prevent the constituents of the mixture from
- 20 separating during subsequent treatments;
- d) the mixture obtained from stage c) is extruded. Exposure time in the extruder is from between 1 and 10, preferably between 4 and 6 minutes, with a temperature profile which ranges from 20°C, preferably 30°C, on entering the extruder to no higher than 120°C, preferably 110°C, on leaving the extruder. Under these
- 25 conditions the PLGA melts forming a continuous matrix which coats the peptide particles while maintaining the heterogeneous nature of these particle dimensions.
- e) the cylinders produced from extrusion may be slightly stretched and then cut to obtain dimensions suitable for the subcutaneous implants, namely a diameter of between 1.0 and 1.7, preferably between 1.3 and 1.5 mm, and a length of between
- 30 10 and 30, preferably between 15 and 24 mm;
- f) finally, if needed, the cylinders obtained from stage e) are sterilised.

Suitable polylactic-glycolic acid copolymers for use in the invention have molecular

weights ranging from 50,000 to 150,000 and a molar ratio between the lactic acid and the glycolic monomer comprised between 50:50 and 95:5.

Preferred polylactic-glycolic acid (PLGA) to be used in the process in accordance with this invention has a high nominal molecular weight, of between 100,000 and 150,000 D, and a molar ratio between lactic monomer and glycolic monomer of  
 5 between 70/30 and 75/25.

The peptides which can be used in this invention are preferably, but not exclusively, analogues of LHRH and comprise, for example

avoreline: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosil-2-methyl-  
 10 D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-prolylamide;  
 tryptoreline: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosil-D-tryptophyl-L-leucyl-L-arginyl-L-prolyl-glicinamide;  
 leuproreline: 5-oxo-L-profil-L-histidyl-L-tryptophyl-L-seryl-L-tyrosil-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolylamide;  
 15 gosereline: - 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosil-tert-butyl-D-seryl-L-leucyl-L-arginyl-L-prolyl-NH-NH-CO-NH<sub>2</sub>.

The peptide preferably used in this invention is avoreline.

The content of peptide in the composition is between 20 and 40%, preferably between 20 and 36% by weight.

20 The quantity of liquid added for granulation is between 10 and 60, preferably between 20 and 45 parts by weight in comparison with the mixture.

The desiccation involved in stage c) takes place at a temperature of between 20-50, preferably between 20-30°C in a current of dry air.

The transversal section of the cylinders obtained from stage f) reveals under  
 25 microscope a heterogeneous structure containing peptide particles having the same granulometry as the initial peptide immersed in the matrix constituted by the PLGA.

The cylinders obtained from stage f) can be successfully used for subcutaneous implants.

30 Each implant having a diameter of between 1.0 and 1.7, preferably between 1.3 and 1.5 mm, and a length of between 10 and 30, preferably between 15 and 24 mm, has a peptide content of between  $\frac{5}{7}$  and  $\frac{25}{15}$  mg.



The peptide released during in vitro and in vivo trials takes place over a time period of at least 6 months.

However the overall time for releasing the peptide can be controlled by varying the diameter and the length of the implant.

- 5 Clinical trials conducted using subcutaneous implants in accordance with this invention in patients with prostate tumours have shown the testosterone suppression within 4 weeks with this effect lasting from approximately 7 months to approximately 12 months.

In order to illustrate the invention the following Examples are quoted.

10 Example 1

10 grams of avoreline were mixed thoroughly with 30 grams of polylactic-glycolic acid (PLGA).

The avoreline had the following characteristics:

- acid-alkalimetric titer : 88.1 % by weight;
- 15 • pKa : 6.15 – 9.70 – 12.02;
- granulometric distribution : between 1 and 60 micrometres.

The PLGA had the following characteristics:

- molecular weight of 116,500 D;
- molar ratio between lactic monomer and glycol monomer: 70: 30;
- 20 • intrinsic viscosity (CHCl<sub>3</sub>); 0.98 dl/g measured at 25°C,
- granulometric distribution : in 90% of cases between 50 and 150 micrometres.

The mixture obtained was granulated wet by adding 16 ml of ethanol using a 16mm grid.

- 25 The granulate obtained was desiccated for 12 hours at a temperature of 25°C in a current of dry air.

After drying the ethanol content in the granulate was 0.66% by weight.

Finally the granulate was extruded using an extruder with a die head of diameter 1.5 mm and length 17.55 mm.

- 30 The speed of rotation of the screws was 5 rev/minute and the temperature was 30°C on entering the extruder and 100°C on leaving the extruder.

The cylinder obtained by the extrusion was slightly stretched and then cut into segments of length 18 mm which were finally radiosterilised. In this way implants

for subcutaneous use with diameter of 1.5 mm, length 18 mm and avoreline content of 25.3% by weight were obtained.

The transversal section of these implants examined under microscope under x275 enlargement reveals a heterogeneous distribution of the particles of avoreline in the mass of PLGA, as shown in Figure 1. In particular the particles of avoreline retain their initial granulometry of between 1 micrometre ad 60 micrometre.

The same microscopic examination was carried out on an implant produced using a known technique obtained in accordance with US 5.366.734 which under 1100x enlargement reveals a homogeneous distribution of the two components as in Figure 2.

#### Kinetics of in vitro release

The implants prepared in accordance with Example 1 were tested in vitro in order to examine the kinetics of releasing avoreline.

The test was carried out under the following conditions.

Five implants were introduced into one flask and the 5 ml of phosphate buffer at pH 7.4 were added. The test was conducted at 37°C for a period of 210 days, continuously stirring the solution using 100 turns per minute.

Each week the buffer solution containing the active constituent released over the same period was sampled and analysed, while 5ml of phosphate buffer were added to the flask as above.

The content of avoreline in the solutions was determined by means of HPLC under the following conditions:

Column: Vydac 218TP 54300A medium, 5 µm,  
dimensions 250 x 4.6 mm

Mobile phase: 750 ml phosphoric acid 0.1M were added to 250 ml of acetonitrile and the pH was corrected to 2.5 with triethylamine and the mixture filtered over an FH type filter (millipore).

Output: 1.5 ml/minute.

Temperature: 30°C

Determination: UV at 220 nm

Injection: volume 10 µl

Analysis time: 15 minutes

The results are shown in Figure 3 in which in the X-axis shows the time expressed in days and the Y-axis shows the cumulative quantity of avoreline released expressed in mg.

#### Example 2

5 Example 1 was repeated, with the difference that implants were produced with a diameter of 1.5 mm, length 15 mm and avoreline content of 20.9% by weight.

Microscopic examination produced similar results to Example 1. The results of the in vitro release test are shown in Figure 4 in which the parameters are the same as those in Figure 3.

#### Example 3

Example 1 was repeated with the difference that PLGA having a molecular weight of 121,900 D was used and implants were prepared having a diameter of 1.5 mm, length 18 mm and avoreline content of 27.9% by weight.

Microscopic examination and the release test produced similar results to Example 1.

#### Example 4

9 grams of avoreline were mixed thoroughly with 24g of polylactic-glycolic acid (PLGA).

The avoreline had the following characteristics:

- 20 • acid-alkalimetric titer : 90.1 % by weight;
- pKa : 6.15 -9.70 -12.02;
- granulometric distribution: between 1 and 60 micrometres.

The PLGA had the following characteristics:

- molecular weight: 121,900 D;
- 25 • molar ratio between lactic monomer and glycolic monomer: 70: 30;
- granulometric distribution : in 90% of cases between 50 and 150 micrometres.

The mixture obtained was granulated wet by adding 6 ml of water using a 1.6mm grid.

The granulate obtained was desiccated for 12 hours at a temperature of 25 °C in a current of dry air.

After drying the water content in the granulate was 1.8% by weight.

Extrusion and the subsequent operations were conducted as in Example 1.

The implants obtained had an avoreline titer of 27.6% by weight.

Microscopic examination and the release test produced similar results to Example 1.

#### Example 5

5 6 grams of tryptoreline were thoroughly mixed with 14 grams of PLGA.

The tryptoreline had a titer of 90.5% by weight and a granulometric distribution of between 1 and 60 micrometres.

The PLGA had a molecular weight of 121,900 D, a molar ratio between lactic monomer and glycolic monomer of 70 : 30 and a 90% granulometric distribution of  
10 between 50 and 150 micrometres.

The mixture obtained was granulated wet by adding 8 ml of ethanol using a 1.6mm grid.

The granulate obtained was desiccated for 12 hours at a temperature of 25°C in a current of dry air.

15 After desiccation the ethanol content in the granulate was 1.0% by weight.

Extrusion and the subsequent operations were conducted as in Example 1.

The implants obtained had an avoreline titer of 24.7% by weight. Microscopic examination and the release test produced similar results to Example 1.

#### Example 6

20 6 grams of gosereline were thoroughly mixed with 14 grams of PLGA.

The gosereline had a titer of 89.5% by weight and a granulometric distribution of between 1 and 60 micrometres.

The PLGA had a molecular weight of 121,900 D, a molar ratio between lactic monomer and glycolic monomer of 70 : 30 and a 90% granulometric distribution  
25 between 50 and 150 micrometres.

The mixture obtained was granulated wet by adding 8 ml of ethanol using a 1.6mm grid.

The granulate was desiccated for 12 hours at a temperature of 25 °C in a current of dry air.

30 After desiccation the ethanol content in the granulate was 1.1% by weight.

Extrusion and the subsequent operations was carried out as in Example 1.

The implants obtained had a gosereline titer of 24.9% by weight.

Microscopic examination and the release test produced similar results to Example 1.

#### Clinical experimentation

Clinical trials were conducted in 60 patients suffering from prostate tumours, using subcutaneous implants prepared in accordance with this invention.

A group of patients was treated with implants having an avoreline content of 10 mg and a second group was treated with implants having an avoreline content of 15 mg.

The results of the experiments are shown in Figures 5 to 8.

The graphs for these Figures can be interpreted as follows:

- Graph a) represents the average plasma concentration of the FSH;
- Graph b) represents the average plasma concentration of testosterone;
- Graph c) represents the average plasma concentration of LH;
- Graph d) represents the average plasma concentration of avoreline;
- line e) is the line of castration with reference to testosterone.

Figure 5 and Figure 7 refer to the use of implants having an avoreline content of 10 mg while Figures 6 and 8 refer to the use of implants having an avoreline content of 15 mg.

With reference to Figures 5 and 6, the left ordinate shows the plasma concentration of LH and FSH expressed in IU/L and the right ordinate shows the plasma concentration of testosterone expressed in nmol/L.

With reference to Figures 7 and 8, the left ordinate shows the plasma concentration of avoreline expressed in pg/mL and the right ordinate shows the plasma concentration of testosterone expressed in nmol/L.

In all the Figures, the time from implant insertion, expressed in weeks, is shown on the X-axis.

As can be seen from these Figures, using the implants in accordance with this invention, testosterone is suppressed within four weeks after the implant is inserted with this effect lasting for a period of between approximately seven months and approximately twelve months.

The plasma concentrations which can be determined for avoreline were measured for approximately 6 months after inserting the implant.

**CLAIMS**

- 1 1. Composition suitable for the preparation of subcutaneous implants having an  
2 extended release time constituted by polylactic-glycolic acid copolymer (PLGA)  
3 and a peptide, characterised by the fact that the peptide particles distributed have  
4 dimensions which are extremely heterogeneous, with peptide particles having a  
5 diameter of between 1 and 60 micrometres dispersed in the PLGA matrix.
- 1 2. Composition in accordance with claim 1, characterised by the fact that when  
2 brought in contact with an aqueous solution of a physiologic type this peptide is  
3 released in three stages, with the first stage of this release involving pure diffusion,  
4 the second stage of release involving the PLGA swelling up and the third stage of  
5 release involving PLGA degradation.
- 1 3. Composition in accordance with claim 1, characterised by the fact that the  
2 aforementioned PLGA has a molecular weight between 50,000 and 150,000 and a  
3 molar ratio between lactic monomer and glycolic monomer comprised between  
4 50:50 and 95:5.
- 1 4. Composition in accordance with claim 3, characterised by the fact that the  
2 aforementioned PLGA has a molecular weight of between 100,000 and 150,000  
3 and a molar ratio between lactic monomer and glycolic monomer of between 70/30  
4 and 75/25.
- 1 5. Composition in accordance with claim 1, characterised by the fact that the  
2 aforementioned peptide is chosen from the group containing avoreline,  
3 tryptoreline, leuproreline and gosereline.
- 1 6. Composition in accordance with claim 1, characterised by the fact that the  
2 aforementioned peptide is avoreline.
- 1 7. Composition in accordance with claim 1, characterised by the fact that the  
2 aforementioned peptide is tryptoreline.
- 1 8. Composition in accordance with claim 1, characterised by the fact that the  
2 aforementioned peptide is gosereline.
- 1 9. Composition in accordance with claim 1, characterised by the fact that the  
2 peptide content is between 20 and 40%, preferably between 20 and 36% by  
3 weight.
- 1 10. Process for preparing compositions suitable for preparing subcutaneous

- 2 implants in accordance with claim 1, characterised by the fact that:
- 3 a) a peptide in the form of particles having a diameter of between 1 and 60  
4 micrometers is homogeneously mixed when dry with PLGA;
- 5 b) the mixture obtained from stage a) is granulated by means of wet granulation  
6 through adding a liquid;
- 7 c) the granulate is dried until the residual liquid content is preferably 0.5 to 2.0% by  
8 weight; and
- 9 d) the mixture obtained from stage c) is extruded and, if needed, cut and sterilised.
- 1 11. Process according to claim 10, characterised by the fact that the exposure  
2 time in the extruder of step d) is from 4 to 6 minutes at a temperature which  
3 ranges from 30°C on entering the extruder to no higher than 110°C on leaving the  
4 extruder.
- 1 12. Process in accordance with claim 10, characterised by the fact that the  
2 quantity of peptide used in stage a) is between 20 and 40% and preferably  
3 between 20 and 36% by weight in comparison with the mixture constituted by the  
4 peptide and PLGA.
- 1 13. Process in accordance with claim 10, characterised by the fact that when this  
2 granulation liquid is ethanol or water the quantity of liquid added is between 10  
3 and 60, preferably between 20 and 45 parts for 100 parts of mixture by weight.
- 1 14. Process in accordance with claim 10, characterised by the fact that the  
2 cylinders obtained by extrusion from stage d) have a diameter of between 1.0 and  
3 1.7, preferably 1.3 and 1.5 mm, and a length of between 10 and 30, preferably 15  
4 and 24 mm.
- 1 15. Subcutaneous implants obtained from the composition as claimed in claim 1.
- 1 16. Subcutaneous implants prepared using the process in accordance with claims  
2 10 to 14.
- 1 17. Subcutaneous implants in accordance with claims 15 and 16 having a  
2 diameter of between 1.3 and 1.5 mm, length of between 15 and 24 mm and  
3 peptide content of between 5 and 20 mg.
- 1 18. Subcutaneous implants in accordance with claim 17, characterised by the fact  
2 that the aforementioned peptide is chosen from the group containing avoreline,  
3 triptoreline, leuproreline and gosereline.




FIGURE 1










FIGURE 2


Figure 3




**Figure 4**









# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09536

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/00 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 134 122 A (ORSOLINI PIERO) 28 July 1992 (1992-07-28) ex. 1 and 3	1,2,5,7, 15,16,18
X	WO 92 11843 A (ALZA CORP) 23 July 1992 (1992-07-23) ex. 5 ("control devices")	1,2,15, 16
X	US 5 445 832 A (ORSOLINI PIERO ET AL) 29 August 1995 (1995-08-29) ex. 1	1,2,5,7, 15,16,18
A	WO 98 09613 A (DEGHENGI ROMANO) 12 March 1998 (1998-03-12) page 5, line 1 -page 6, line 32 ex. 1	1-18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 Apr11 2000

Date of mailing of the international search report

08/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5816 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Borst, M



# INTERNATIONAL SEARCH REPORT

In ternational Application No  
PCT/EP 99/09536

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 192 741 A (DEGHENGHI ROMANO ET AL) 9 March 1993 (1993-03-09) column 1, line 67 -column 2, line 35 ex. 1 -----	1-18
A	YUNG-YUEH HSU ET AL: "IN VITRO CONTROLLED RELEASE OF ISONIAZID FROM POLY(LACTIDE-CO- FLUCOLIDE) MATRICES" JOURNAL OF CONTROLLED RELEASE, NL, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 31, no. 3, 1 October 1994 (1994-10-01), pages 223-228, XP000469851 ISSN: 0168-3659 paragraph "4. Summary and conclusions" page 228, left-hand column -----	1-18

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/EP 99/09536

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5134122	A	28-07-1992	CH 679207 A	15-01-1992
			AT 397197 B	25-02-1994
			AU 619996 B	06-02-1992
			AU 5910390 A	31-01-1991
			BE 1003093 A	19-11-1991
			CA 2021767 A,C	29-01-1991
			DE 4023134 A	31-01-1991
			DK 180790 A	29-01-1991
			ES 2020890 A	01-10-1991
			FI 97688 B	31-10-1996
			FR 2650182 A	01-02-1991
			GB 2234169 A,B	30-01-1991
			GR 90100568 A,B	10-12-1991
			IE 65397 B	18-10-1995
			IL 95120 A	07-10-1994
			IT 1243357 B	10-06-1994
			JP 1933192 C	26-05-1995
			JP 3066625 A	22-03-1991
			JP 6062427 B	17-08-1994
			LU 87772 A	11-12-1990
			NL 9001646 A	18-02-1991
			NO 300304 B	12-05-1997
			PT 94842 A,B	20-03-1991
			SE 504279 C	23-12-1996
			SE 9002522 A	29-01-1991
			US 5439688 A	08-08-1995
			US 5225205 A	06-07-1993
			ZA 9005654 A	29-05-1991
WO 9211843	A	23-07-1992	MX 9200038 A	01-11-1992
			PT 99989 A	31-05-1994
			US 5543156 A	06-08-1996
			ZA 9200088 A	28-10-1992
US 5445832	A	29-08-1995	CH 683149 A	31-01-1994
			AT 403348 B	26-01-1998
			AT 148992 A	15-06-1997
			AU 651711 B	28-07-1994
			AU 2043692 A	28-01-1993
			AU 652844 B	08-09-1994
			AU 2043792 A	28-01-1993
			BE 1005696 A	21-12-1993
			BE 1005697 A	21-12-1993
			BR 9205375 A	08-03-1994
			CA 2074320 A,C	23-01-1993
			CA 2074322 A	23-01-1993
			CH 683592 A	15-04-1994
			WO 9301802 A	04-02-1993
			CN 1070344 A	31-03-1993
			CZ 9300660 A	19-01-1994
			DE 4223282 A	28-01-1993
			DE 4223284 A	28-01-1993
			DE 9219084 U	25-09-1997
			DK 93892 A	23-01-1993
			DK 93992 A	23-01-1993
			ES 2037621 B	01-02-1994
			ES 2050070 A	01-05-1994
			FI 923320 A	23-01-1993

# INTERNATIONAL SEARCH REPORT

In International Application No

PCT/EP 99/09536

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5445832 A		FI 923321 A	23-01-1993
		FR 2679450 A	29-01-1993
		FR 2680109 A	12-02-1993
		GB 2257909 A,B	27-01-1993
		GB 2257973 A,B	27-01-1993
		GR 1001446 B	30-12-1993
		GR 92100323 A,B	24-05-1993
		HR 920229 A	30-04-1996
		HU 64234 A	28-12-1993
		IE 69967 B	16-10-1996
		IE 71199 B	12-02-1997
		IL 102590 A	13-07-1997
		IL 102591 A	10-06-1997
		IT 1259891 B	28-03-1996
		IT 1259892 B	28-03-1996
		JP 6172208 A	21-06-1994
		JP 2842736 B	06-01-1999
		JP 5221855 A	31-08-1993
		LU 88150 A	15-02-1993
		LU 88151 A	15-02-1993
		MX 9204268 A	31-03-1994
		NL 9201309 A	16-02-1993
		NL 9201310 A	16-02-1993
		NO 304136 B	02-11-1998
		NO 304057 B	19-10-1998
		NZ 243643 A	26-10-1993
WO 9809613 A	12-03-1998	US 5945128 A	31-08-1999
		AU 713123 B	25-11-1999
		AU 4012197 A	26-03-1998
		BR 9706741 A	20-07-1999
		CA 2236595 A	12-03-1998
		CN 1200032 A	25-11-1998
		EP 0858323 A	19-08-1998
		JP 11514678 T	14-12-1999
US 5192741 A	09-03-1993	GB 2209937 A	01-06-1989
		AT 397035 B	25-01-1994
		AU 2232688 A	23-03-1989
		BE 1001685 A	06-02-1990
		CA 1326438 A	25-01-1994
		CH 675968 A	30-11-1990
		DE 3822459 A	30-03-1989
		DK 518988 A	22-03-1989
		ES 2009346 A	16-09-1989
		FI 884297 A,B,	22-03-1989
		FR 2620621 A	24-03-1989
		GR 88100619 A,B	22-06-1989
		IE 60608 B	27-07-1994
		IL 87790 A	25-05-1992
		IT 1225148 B	02-11-1990
		JP 1121222 A	12-05-1989
		JP 1981991 C	25-10-1995
		JP 7013023 B	15-02-1995
		LU 87340 A	06-04-1989
		NL 8802323 A	17-04-1989
		NO 178604 B	22-01-1996
		PT 88557 A,B	01-10-1988

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/09536

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5192741 A		SE 503406 C	10-06-1996
		SE 8803321 A	22-03-1989
		US 5776885 A	07-07-1998
		ZA 8806827 A	30-05-1989
<hr/>			